X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PRGN-2012
Therapeutic Area: Rare Diseases and Disorders Product Name: PRGN-2012
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021
Details:
PRGN-2012 is under development through a Cooperative Research and Development Agreement (CRADA) with the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RP-L401
Therapeutic Area: Rare Diseases and Disorders Product Name: RP-L401
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: California Institute for Regenerative Medicine
Deal Size: $3.7 million Upfront Cash: Undisclosed
Deal Type: Funding November 13, 2020
Details:
Clinical Grant of $3.7 M to Fund US Phase 1 Study of RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis. This will be Rocket’s second CIRM grant after receiving one in 2019 for the development of the company’s gene therapy for Leukocyte Adhesion Deficiency-I.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
